Givosiran · GIVLAARI

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Acute Hepatic Porphyria

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
JP
  • Treatment of acute hepatic porphyria
Product first approved 2021PMDA
CA
  • Givlaari: acute hepatic porphyria in adults
Product first approved 2020dhpp.hpfb-dgpsa.ca
EU
  • Acute hepatic porphyria in adults and adolescents aged 12 years and older
Product first approved 2020EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Acute Hepatic Porphyria
Phase 1/2 (1)
Other / comorbidity
NCT02949830 · Alnylam Pharmaceuticals
2016-10 – 2021-11-05 · Acute Intermittent Porphyria
What this study did
Phase 1 (2)
Acute Hepatic Porphyria
NCT03505853 · Alnylam Pharmaceuticals
2018-04-26 – 2019-01-10 · Acute Intermittent Porphyria (AIP), Acute Hepatic Porphyria (AHP), Porphyria, Acute Intermittent, Acute Porphyria
What this study did
Other / comorbidity
NCT02452372 · Alnylam Pharmaceuticals
2015-05-06 – 2017-09-06 · Acute Intermittent Porphyria
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.